LIFECORE BIOMEDICAL, INC. Fair Value Inputs, Discount Rate (Deprecated 2018-01-31)
LIFECORE BIOMEDICAL, INC. (LFCR) reported Fair Value Inputs, Discount Rate (Deprecated 2018-01-31) of 12.00% for the 9-month period ending 2018-02-25, per its 10-Q filed 2018-04-05.
Discontinued › Notes › Fair Value Measures and Disclosures
us-gaap:FairValueInputsDiscountRate · last filed 2018-04-05
- LIFECORE BIOMEDICAL, INC. fair value inputs, discount rate (deprecated 2018-01-31) for the quarter ending 2017-08-27 was 12.00%.
- LIFECORE BIOMEDICAL, INC. fair value inputs, discount rate (deprecated 2018-01-31) for fiscal 2016 was 12.50%.
| Period end | Fair Value Inputs, Discount Rate (Deprecated 2018-01-31) 3 month | Fair Value Inputs, Discount Rate (Deprecated 2018-01-31) 6 month | Fair Value Inputs, Discount Rate (Deprecated 2018-01-31) 9 month | Fair Value Inputs, Discount Rate (Deprecated 2018-01-31) 12 month |
|---|---|---|---|---|
| 2018-02-25 | 12.00% 10-Q · filed 2018-04-05 | |||
| 2017-11-26 | 12.00% 10-Q · filed 2018-01-05 | |||
| 2017-08-27 | 12.00% 10-Q · filed 2017-09-28 | |||
| 2017-05-28 | 12.00% 10-Q · filed 2018-04-05 | |||
| 2017-02-26 | 12.00% 10-Q · filed 2017-04-07 | |||
| 2016-11-27 | 12.00% 10-Q · filed 2017-01-05 | |||
| 2016-05-29 | 12.50% 10-K/A · filed 2018-03-15 | |||
| 2016-02-28 | 12.50% 10-Q · filed 2016-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 | |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B |